China News Service, Beijing, April 12 (Reporter Zhao Jianhua) Inflated drug prices are a chronic disease hated by the public.
The Ministry of Finance of the People's Republic of China, together with the National Medical Insurance Administration, will implement accounting information quality inspections on 77 pharmaceutical companies in 2019, focusing on the cost structure of pharmaceutical products.
The Ministry of Finance issued an announcement on the 12th that the inspection has found out the cause of the falsely high drug prices, deterred pharmaceutical companies from paying for sales, driving up drug prices and other violations, and ensuring the smooth progress of major reforms such as centralized drug purchases.
After investigation, some pharmaceutical companies have the following problems: one is the use of false invoices and bills to arbitrage funds for external use; the other is fictitious business matters or the use of medical promotion companies to arbitrage funds; the third is other accounting problems such as irregular accounting books.
The above behavior violates Article 9 of the Chinese Accounting Law and other provisions.
The so-called sale with gold refers to the fact that when pharmaceutical companies formulate drug bidding prices, they include in advance the commercial bribes given to prescribing doctors and people with decision-making power and influence on drug purchases, and they seek to obtain trading opportunities or competitive advantages by giving rebates.
According to Article 42 of the Accounting Law, the Ministry of Finance imposed administrative penalties on 19 pharmaceutical companies inspected by the relevant supervision bureau of the Ministry of Finance.
For other pharmaceutical companies, the Department of Finance (Bureau) responsible for the inspection shall impose administrative punishments on the spot.
Other violations of laws and regulations found in the inspection shall be transferred to the competent authority for handling.
The 19 pharmaceutical companies that have been punished include: Beijing Cheng Nuo Mei Di Technology Co., Ltd., Sanofi (Beijing) Pharmaceutical Co., Ltd., Changbai Mountain Pharmaceutical Co., Ltd., Tonghua Yusheng Pharmaceutical Co., Ltd., Jiangsu Wanbang Pharmaceutical Marketing Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai Xinyi United Pharmaceutical Co., Ltd., Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., Shanghai Xinyi Tianyi Pharmaceutical Co., Ltd., Shandong Xinyi Pharmaceutical Co., Ltd., Fujian Gutian Pharmaceutical Co., Ltd., Shandong Buchang Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Jiangsu Hausen Pharmaceutical Group Co., Ltd., Eli Lilly (Shanghai) Management Co., Ltd., Guangdong Yili Pharmaceutical Co., Ltd., Yili Pharmaceutical (Luoding) Co., Ltd. , Shenzhen China Resources Sanjiu Pharmaceutical Trading Co., Ltd., Yunnan Longhai Natural Plant Pharmaceutical Co., Ltd.
They were fined 30,000 yuan or 50,000 yuan (RMB, the same below) by the Ministry of Finance.
The person in charge of the relevant department of the Ministry of Finance stated that according to the relevant provisions of the Accounting Law, a fine of 50,000 yuan is the top penalty.
In the future, we will intensify law enforcement inspections, effectively improve the quality of accounting and auditing, protect public interests and implement major reforms.
(Finish)